<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405261</url>
  </required_header>
  <id_info>
    <org_study_id>NN9926-3894</org_study_id>
    <secondary_id>U1111-1119-1560</secondary_id>
    <secondary_id>2011-000297-57</secondary_id>
    <nct_id>NCT01405261</nct_id>
  </id_info>
  <brief_title>Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects</brief_title>
  <official_title>Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate safety,
      tolerability and pharmacokinetics (the exposure of the trial drug in the body) of single
      doses of NNC 0113-0987 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overview of Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>Up to 25 days after trial product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypoglycaemic episodes</measure>
    <time_frame>From screening (day 1-21 before trial product administration) and until completion of the post treatment follow-up visit (day 12-25 after trial product administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-240h; area under the NNC 0113-0987 concentration-time curve</measure>
    <time_frame>From time 0 to 240 hours after a single oral or intravenous (i.v.) dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC, area under the curve</measure>
    <time_frame>From time 0 to infinity after a single oral or i.v. dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax; maximum concentration of NNC 0113-0987 in plasma</measure>
    <time_frame>After a single oral or i.v. dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to maximum concentration (tmax) of NNC 0113-0987 in plasma</measure>
    <time_frame>After a single oral dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NNC 0113-0987 (gastro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC 0113-987 (coated)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC 0113-987 (i.v)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral NNC 0113-0987</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.</description>
    <arm_group_label>NNC 0113-0987 (gastro)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral NNC 0113-0987</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.</description>
    <arm_group_label>NNC 0113-987 (coated)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I.v. NNC 0113-0987</intervention_name>
    <description>Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.</description>
    <arm_group_label>NNC 0113-987 (i.v)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <description>Subjects will be randomised to receive a single dose of placebo.</description>
    <arm_group_label>NNC 0113-0987 (gastro)</arm_group_label>
    <arm_group_label>NNC 0113-987 (coated)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects with good general health as judged by the investigator, based on medical
             history, physical examination including 12-lead electrocardiogram (ECG), vital signs,
             and blood and urinary laboratory assessments at the screening visit

          -  Body Mass Index (BMI) of minimum 18.5 and below 30 kg/m^2

        Exclusion Criteria:

          -  Male subjects who are sexually active and not surgically sterilised, who or whose
             partner are unwilling to use two different forms of effective contraception, one of
             which has to be a barrier method (e.g. condom with spermicidal foam/gel/film/cream)
             for the duration of the trial and for 3 months following the last dose of trial
             medication

          -  The receipt of any investigational product within 90 days (or 5 half-lives of
             investigational drug, whichever is greater) prior to this trial (screening), or is
             currently enrolled in any other clinical trial

          -  Subjects with a history of or presence of cancer, diabetes, or any clinically
             significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,
             endocrinological, haematological, dermatological, venereal, neurological, psychiatric
             diseases or other major disorders that might have impact on the current trial, as
             judged by the investigator

          -  Subjects who are known to have hepatitis or who are carriers of the Hepatitis B
             surface antigen (HBsAg) or Hepatitis C antibodies, or have a positive result to the
             test for Human Immunodeficiency Virus (HIV) antibodies

          -  History of chronic or idiopathic acute pancreatitis or amylase or lipase values above
             3x upper normal range (UNR)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

